华府在毛发失落的药物处方方面领先美国,在收入、保险和地区方面存在重大差异。 D.C. leads U.S. in hair-loss drug prescriptions, with major disparities tied to income, insurance, and region.

一项新的分析显示,美国在理发药处方方面差异很大,华盛顿特区是全国平均水平的五倍以上,明尼苏达州位居第21位,最低,为0.44%。 A new analysis shows wide U.S. disparities in hair-loss medication prescriptions, with Washington D.C. leading at over five times the national average, while Minnesota ranks 21st lowest at 0.44%. 高收入城市地区的利用率较高,这与收入、城市化和外观问题有关,而西弗吉尼亚州、密西西比州和北达科他州等南方和中西部州的比率最低。 Higher-income urban areas see greater use, linked to income, urbanization, and appearance concerns, while Southern and Midwestern states like West Virginia, Mississippi, and North Dakota have the lowest rates. 保险覆盖是一个关键因素:大约70%的商业保险患者使用仿制品芬胺,但品牌Propecia和非标签口服胺酸通常被排除在外,Medicare几乎没有提供保险. Insurance coverage is a key factor: about 70% of commercially insured patients access generic finasteride, but brand-name Propecia and off-label oral minoxidil are often excluded, and Medicare offers nearly no coverage. 男性型秃头影响到5 000多万男子,与基因有关,与心脏病、糖尿病和心理健康问题的较高风险相关。 Male-pattern baldness affects over 50 million men, is genetically linked, and tied to higher risks of heart disease, diabetes, and mental health issues. 治疗包括局部用米诺克西迪尔和口服费纳斯特,尽管获得率大大不同. Treatments include topical minoxidil and oral finasteride, though access varies significantly.